• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

What is the true incidence of COVID-19 in patients with rheumatic diseases?

作者信息

Favalli Ennio Giulio, Ingegnoli Francesca, Cimaz Rolando, Caporali Roberto

机构信息

Division of Clinical Rheumatology, Gaetano Pini-CTO, Milano, Lombardia, Italy

Division of Clinical Rheumatology, Gaetano Pini-CTO, Milano, Lombardia, Italy.

出版信息

Ann Rheum Dis. 2021 Feb;80(2):e18. doi: 10.1136/annrheumdis-2020-217615. Epub 2020 Apr 22.

DOI:10.1136/annrheumdis-2020-217615
PMID:32321723
Abstract
摘要

相似文献

1
What is the true incidence of COVID-19 in patients with rheumatic diseases?风湿性疾病患者中新型冠状病毒肺炎的真实发病率是多少？
Ann Rheum Dis. 2021 Feb;80(2):e18. doi: 10.1136/annrheumdis-2020-217615. Epub 2020 Apr 22.
2
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.风湿性疾病患者因 COVID-19 住院的相关特征：来自 COVID-19 全球风湿病联盟医生报告登记处的数据。
Ann Rheum Dis. 2020 Jul;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871. Epub 2020 May 29.
3
Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.接受生物和合成靶向治疗的风湿性疾病患者中COVID-19的临床特征和结局
Ann Rheum Dis. 2020 Jul;79(7):988-990. doi: 10.1136/annrheumdis-2020-217948. Epub 2020 Jun 5.
4
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.COVID-19 住院患者合并慢性炎症和自身免疫性风湿性疾病的临床结局：一项多中心匹配队列研究。
Ann Rheum Dis. 2020 Dec;79(12):1544-1549. doi: 10.1136/annrheumdis-2020-218296. Epub 2020 Aug 12.
5
Self-protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: results and predictors in more than 12 000 patients with inflammatory rheumatic diseases followed in the Danish DANBIO registry.在 COVID-19 大流行期间，炎症性风湿病患者的自我保护策略和健康行为：丹麦 DANBIO 注册中心随访的 12000 多名炎症性风湿病患者的结果和预测因素。
RMD Open. 2021 Jan;7(1). doi: 10.1136/rmdopen-2020-001505.
6
Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.炎症性肠病在治疗炎症性风湿性疾病的抗 TNF-α 治疗期间的发展：全国系列研究。
Joint Bone Spine. 2012 Oct;79(5):457-63. doi: 10.1016/j.jbspin.2011.10.001. Epub 2011 Nov 15.
7
Biologics, spondylitis and COVID-19.生物制剂、脊柱炎与新型冠状病毒肺炎
Ann Rheum Dis. 2020 Dec;79(12):1663-1665. doi: 10.1136/annrheumdis-2020-217941. Epub 2020 Jun 10.
8
Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases.COVID-19 相关住院风险因素在自身免疫性炎症性风湿病患者中的分析。
Ann Rheum Dis. 2020 Nov;79(11):1393-1399. doi: 10.1136/annrheumdis-2020-217984. Epub 2020 Aug 7.
9
Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases.一组患有风湿性疾病的COVID-19患者的临床病程、严重程度和死亡率。
Ann Rheum Dis. 2020 Dec;79(12):1659-1661. doi: 10.1136/annrheumdis-2020-218054. Epub 2020 Jun 30.
10
Biologics in systemic autoimmune diseases during COVID-19 pandemic.新冠疫情期间系统性自身免疫性疾病中的生物制剂
Clin Rheumatol. 2020 Dec;39(12):3529-3531. doi: 10.1007/s10067-020-05439-z. Epub 2020 Oct 4.

引用本文的文献

1
Frequency, characteristics and outcome of corona virus disease 2019 (COVID-19) infection in Iranian patients with rheumatic diseases.伊朗风湿性疾病患者中2019冠状病毒病（COVID-19）感染的频率、特征及结果
Egypt Rheumatol. 2022 Jun;44(3):209-213. doi: 10.1016/j.ejr.2021.12.002. Epub 2021 Dec 10.
2
Cross-sectional study of COVID-19 infection in patients with rheumatic diseases in a sample of a Damascene population, Syria.叙利亚大马士革人群样本中风湿病患者新冠病毒感染的横断面研究。
Ann Med Surg (Lond). 2023 Mar 14;85(4):689-693. doi: 10.1097/MS9.0000000000000274. eCollection 2023 Apr.
3
IFI44 is an immune evasion biomarker for SARS-CoV-2 and infection in patients with RA.
IFI44 是 SARS-CoV-2 的免疫逃逸生物标志物，与 RA 患者的感染相关。
Front Immunol. 2022 Sep 15;13:1013322. doi: 10.3389/fimmu.2022.1013322. eCollection 2022.
4
Prevalence of coronavirus disease 2019 in a multiethnic cohort of patients with autoimmune rheumatic diseases in Qatar.卡塔尔自身免疫性风湿病多民族患者队列中2019冠状病毒病的患病率
Qatar Med J. 2022 Aug 5;2022(3):37. doi: 10.5339/qmj.2022.37. eCollection 2022.
5
Can anti-TNFα Antibodies Affect SARS-CoV-2 Disease Outcomes?抗TNFα抗体能否影响新冠病毒疾病的转归？
Adv Pharm Bull. 2022 May;12(3):423. doi: 10.34172/apb.2022.066. Epub 2021 Oct 9.
6
Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study.风湿免疫性炎症性疾病未免疫患者 COVID-19 的抗体产生和疾病严重程度：来自前瞻性队列研究的数据。
RMD Open. 2022 Apr;8(1). doi: 10.1136/rmdopen-2021-002035.
7
Attitudes of patients with spondylarthritis or rheumatoid arthritis regarding biological treatment during COVID-19 pandemic: A multi-center, phone-based, cross-sectional study.脊柱关节炎或类风湿关节炎患者在 COVID-19 大流行期间对生物治疗的态度：一项基于电话的多中心横断面研究。
Arch Rheumatol. 2021 Jun 24;36(4):473-481. doi: 10.46497/ArchRheumatol.2021.8364. eCollection 2021 Dec.
8
The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study.抗风湿药物对炎症性关节炎患者队列中抗SARS-CoV-2抗体血清阳性率的影响：主流研究
Front Med (Lausanne). 2022 Mar 11;9:850858. doi: 10.3389/fmed.2022.850858. eCollection 2022.
9
Severity and mortality of COVID-19 in patients with systemic sclerosis: a Brazilian multicenter study.系统性硬化症患者 COVID-19 的严重程度和死亡率：巴西多中心研究。
Semin Arthritis Rheum. 2022 Aug;55:151987. doi: 10.1016/j.semarthrit.2022.151987. Epub 2022 Feb 25.
10
Coronavirus disease 2019 in patients with Behcet's disease: a report of 59 cases in Iran.白塞病患者中的2019冠状病毒病：伊朗59例报告
Clin Rheumatol. 2022 Apr;41(4):1177-1183. doi: 10.1007/s10067-021-06004-y. Epub 2021 Nov 29.